Get started
Author

Jing Wang

Venetoclax Plus Gilteritinib for FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia
2022 · Naval Daver, Alexander E. Perl, et al. · Journal of Clinical Oncology · 202
PDF
Coinfusion of Mesenchymal Stromal Cells Facilitates Platelet Recovery Without Increasing Leukemia Recurrence in Haploidentical Hematopoietic Stem Cell Transplantation: A Randomized, Controlled Clinical Study
2010 · Kaiyan Liu, Yuhong Chen, et al. · Stem Cells and Development · 89
Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission
2018 · Meng Lv, Yu Wang, et al. · Clinical Cancer Research · 44
Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
2017 · Jing Wang, Qian Jiang, et al. · Transplantation and Cellular Therapy · 43
PDF
The loss or absence of minimal residual disease of <0·1% at any time after two cycles of consolidation chemotherapy in CBFB–MYH11‐positive acute myeloid leukaemia indicates poor prognosis
2020 · Wenbing Duan, Xiaohong Liu, et al. · British Journal of Haematology · 25
PDF
High EVI1 Expression Predicts Poor Outcomes in Adult Acute Myeloid Leukemia Patients with Intermediate Cytogenetic Risk Receiving Chemotherapy
2018 · Ya-Zhen Qin, Ting Zhao, et al. · Medical Science Monitor · 25
PDF
Interferon-α as maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia
2021 · Hao Jiang, Xiao-Hong Liu, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 23
Detection of measurable residual disease may better predict outcomes than mutations based on next‐generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA
2020 · Jing Wang, RunQing Lu, et al. · British Journal of Haematology · 23
Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center
2021 · Wenbing Duan, Xiaohong Liu, et al. · Annals of Hematology · 22
COVID ‐19 infection in patients with haematological malignancies: A single‐centre survey in the latest Omicron wave in China
2023 · Xiaolu Zhu, Qian Jiang, et al. · British Journal of Haematology · 15
Risk Stratification of Cytogenetically Normal Acute Myeloid Leukemia With Biallelic CEBPA Mutations Based on a Multi-Gene Panel and Nomogram Model
2021 · Li-Xin Wu, Hao Jiang, et al. · Frontiers in Oncology · 12
PDF
Bone marrow macrophages are involved in the ineffective hematopoiesis of myelodysplastic syndromes
2024 · Tong Xing, Wei‐Li Yao, et al. · Journal of Cellular Physiology · 10
Comparison of efficacy between homoharringtonine, aclarubicin, cytarabine (HAA) and idarubicin, cytarabine (IA) regimens as induction therapy in patients with de novo core binding factor acute myeloid leukemia
2023 · Wenbing Duan, Sen Yang, et al. · Annals of Hematology · 9
PML‐RARA transcript levels at the end of induction therapy are associated with prognosis in non‐high‐risk acute promyelocytic leukaemia with all‐trans retinoic acid plus arsenic in front‐line therapy: long‐term follow‐up of a single‐centre cohort study
2021 · Fei‐Fei Tang, Sheng‐Ye Lu, et al. · British Journal of Haematology · 8
PDF
[Comparison of 10 mg/m² or 8 mg/m² idarubicin plus cytarabine regimen as induction chemotherapy for adult patients with newly diagnosed acute myeloid leukemia].
2015 · Yuanyuan Zhang, Shenmiao Yang, et al. · PubMed · 8
A Case of Bernard-Soulier Syndrome due to a Novel Homozygous Missense Mutation in an Exon of the GP1BA Gene
2019 · Xingchuan Li, Song Wang, et al. · Acta Haematologica · 6
Sintilimab plus decitabine for higher-risk treatment-naïve myelodysplastic syndromes: efficacy, safety, and biomarker analysis of a phase II, single-arm trial
2024 · Jing Wang, Siqi Li, et al. · Journal for ImmunoTherapy of Cancer · 5
PDF
Patients with Philadelphia-positive leukemia with Y253H or F359V mutation have a high risk of developing new mutations in the setting of dasatinib resistance
2014 · Qian Jiang, Ya-Zhen Qin, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 5
Only FLT3-ITD co-mutation did not have a deleterious effect on acute myeloid leukemia patients with NPM1 mutation, but concomitant with DNMT3A co-mutation or a < 3log reduction of MRD2 predicted poor survival
2024 · Wenbing Duan, Jinsong Jia, et al. · Annals of Hematology · 4
Venetoclax and Hypomethylating Agent in Previously Untreated Higher‐Risk Myelodysplastic Syndromes and Genotype Signatures for Response and Prognosis: A Real‐World Study
2024 · Jing Wang, Zhijian Fang, et al. · American Journal of Hematology · 3
[Clinical features and prognosis in MLL-AF10 positive acute leukemia].
2015 · Li'na Wang, Yazhen Qin, et al. · PubMed · 3
[The relationship between induction chemotherapy cycles and prognosis in patients with acute myeloid leukemia].
2015 · Ting Zhao, Yuanyuan Zhang, et al. · PubMed · 3
[Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy].
2014 · Jing Wang, Xiaojun Huang, et al. · PubMed · 3
An Analysis of Incidence, Related Factors and Prophylactic Treatments of Hospital-Acquired Upper Extremity Deep Vein Thrombosis: A Single-Center 13-Year Retrospective Study
2025 · Xiao Wang, Yezu Liu, et al. · Clinical and Applied Thrombosis/Hemostasis · 2
Comparison of Safety and Efficacy between Venetoclax Combined with CAG (cytarabine, aclarubicin, G-CSF) Regimen and CAG Regimen Alone in Patients with Relapsed or Refractory Acute Myeloid Leukemia
2023 · Wen-Jing Yu, Ying Wu, et al. · Blood · 2
PDF
Works count: 48
Citation count: 601
H-index: 11
I10-index: 12
Year
Topic
Type